Women and von Willebrand Disease: Controversies in Diagnosis and Management

ABSTRACT

von Willebrand disease (vWD) is the commonest bleeding disorder in women. More than 70% of women with vWD suffer from menorrhagia and half of them suffer from dysmenorrhea. There is also the risk of hemorrhage with ovulation and mid-cycle pain. These have a significant effect on all aspects of quality of life. vWD also can be the underlying cause of menorrhagia in a small but significant proportion of women. There are still several unanswered issues in the diagnosis and management of menorrhagia in these women. There is no consensus whether testing for vWD should be part of the routine investigations in menorrhagia. Diagnosis of vWD is difficult. There are intraindividual variations in von Willebrand factor and factor VIII levels influenced by age, race, and blood group. This is further complicated in women because of the fluctuation of these factor levels during the menstrual cycle and possibly with hormonal therapy. The diagnosis of menorrhagia is also difficult due to the lack of a simple objective tool for the assessment of menstrual blood loss. In vWD, the treatment of menorrhagia is usually medical, but there is lack of prospective data on the efficacy of commonly used medical therapies in these women. The levonorgestrel intrauterine system, Mirena, is effective and should be considered prior to surgical management. Surgical interventions may be required in patients unresponsive to medical treatments. These procedures can be complicated by hemorrhage in these women. A multidisciplinary approach in the management of these women is essential in ensuring an optimal outcome. Multicenter clinical trials are required to answer the controversial issues in the management of women with vWD.

von Willebrand disease - women - menorrhagia - management - diagnosis

REFERENCES

• 1 Federici A B, Mannucci P M. Actual management of von Willebrand disease: first report on 880 cases of the Italian registry of VWD.  Blood. 1997;  90 33a , (abst)
• 2 Foster P A. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost. 1995;  74 784-790
• 3 Ragni M V, Bontempo F A, Hassett A C. von Willebrand disease and bleeding in women.  Haemophilia. 1999;  5 313-317
• 4 Kadir R A, Economides D L, Sabin C A, Pollard D, Lee C A. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders.  Haemophilia. 1999;  5 40-48
• 5 Kouides P A, Phatak P D, Burkart P et al.. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey.  Haemophilia. 2000;  6 643-648
• 6 Rozeik C, Scharrer I. Gynecological disorders and psychological problems in 184 women with von Willebrand disease.  Haemophilia. 1998;  4 293
• 7 Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study.  Haemophilia. 2003;  9 292-297
• 8 James A H. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders.  Haemophilia. 2005;  11 295-307
• 9 Barr R D, Sek J, Horsman J et al.. Health status and health-related quality of life associated with von Willebrand disease.  Am J Hematol. 2003;  73 108-114
• 10 Barr R D, Saleh M, Furlong W et al.. Health status and health-related quality of life associated with hemophilia.  Am J Hematol. 2002;  71 152-160
• 11 Whitton A C, Rhydderch H, Furlong W, Feeny D, Barr R D. Self-reported comprehensive health status of adult brain tumor patients using the Health Utilities Index.  Cancer. 1997;  80 258-265
• 12 Kadir R A, Sabin C, Pollard D, Lee C, Economides D L. Quality of life during menstruation in patients with inherited bleeding disorders.  Haemophilia. 1998;  4 836-841
• 13 Bruner A B, Joffe A, Duggan A K, Casella I F, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls.  Lancet. 1996;  348 992-996
• 14 Patterson A J, Brown W J, Roberts D CK. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age.  J Am Coll Nutr. 2001;  20 337-342
• 15 Shankar M, Lee C A, Sabin C A, Economides D L, Kadir R A. von Willebrand disease in women with menorrhagia: a systematic review.  BJOG. 2004;  111 734-740
• 16 James A, Matchar D B, Myers E R. Testing for von Willebrand disease in women with menorrhagia: a systematic review.  Obstet Gynecol. 2004;  104 381-388
• 17 Philipp C S, Faiz A, Dowling N et al.. Age and the prevalence of bleeding disorders in women with menorrhagia.  Obstet Gynecol. 2005;  105 61-66
• 18 American College of Obstetricians and Gynecologists Committee Opinion No 263 . von Willebrand's disease in gynecologic practice.  Obstet Gynecol. 2001;  98 1185-1186
• 19 Dilley A, Drews C, Lally C, Austin H, Barnhart E, Evatt B. A survey of gynecologists concerning menorrhagia: perceptions of bleeding disorders as a possible cause.  J Womens Health Gend Based Med. 2002;  11 39-44
• 20 Chi C, Shiltagh N, Kingman C EC, Economides D L, Lee C A, Kadir R A. Identification and management of women with inherited bleeding disorders: a survey of obstetricians and gynaecologists in the United Kingdom.  Haemophilia. 2006;  12 405-412
• 21 Kadir R A, Economides D L, Sabin C A, Owens D, Lee C A. Frequency of inherited bleeding disorders in women with menorrhagia.  Lancet. 1998;  351 485-489
• 22 Quiroga T, Goycoolea M, Munoz B et al.. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients.  J Thromb Haemost. 2004;  2 892-898
• 23 James A H, Lukes A S, Brancazio L R, Thames E, Ortel T L. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia.  Am J Obstet Gynecol. 2004;  191 449-455
• 24 Kouides P A, Conard J, Peyvandi F, Lukes A, Kadir R. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding.  Fertil Steril. 2005;  84 1345-1351
• 25 Rodeghiero F, Castaman G, Tosetto A et al.. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.  J Thromb Haemost. 2005;  3 2619-2626
• 26 Fraser I S, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume.  Am J Obstet Gynecol. 1984;  149 788-793
• 27 Chimbira T H, Anderson A BM, Turnbull A C. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area.  Br J Obstet Gynaecol. 1980;  87 603-609
• 28 Hallberg L, Hogdahl A M, Nilsson L, Rybo G. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality.  Acta Obstet Gynecol Scand. 1966;  45 320-351
• 29 Hallberg L, Nilsson L. Determination of menstrual blood loss.  Scand J Clin Lab Invest. 1964;  16 244-248
• 30 Warner P E, Critchley H O, Lumsden M A, Campbell-Brown M, Douglas A, Murray G D. Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia?.  Am J Obstet Gynecol. 2004;  190 1224-1229
• 31 Warner P E, Critchley H O, Lumsden M A, Campbell-Brown M, Douglas A, Murray G D. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data.  Am J Obstet Gynecol. 2004;  190 1216-1223
• 32 Higham J M, O'Brien P M, Shaw R W. Assessment of menstrual blood loss using a pictorial chart.  Br J Obstet Gynaecol. 1990;  97 734-739
• 33 Janssen C A, Scholten P C, Heintz A P. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss.  Obstet Gynecol. 1995;  85 977-982
• 34 Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States.  Haemophilia. 2004;  10 158-161
• 35 Kadir R A, Economides D L, Sabin C A, Owens D, Lee C A. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive.  Thromb Haemost. 1999;  82 1456-1461
• 36 Miller C H, Dilley A, Richardson L, Hooper W C, Evatt L. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women.  Am J Hematol. 2001;  67 125-129
• 37 Sukhu K, Poovalingam V, Mahomed R, Giangrande P LF. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease.  Clin Lab Haematol. 2003;  25 247-249
• 38 Dilley A, Drews C, Miller C et al.. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.  Obstet Gynecol. 2001;  97 630-636
• 39 Gill J C, Endres-Brooks J, Bauer P J, Marks W J, Montgomery R R. The effect of ABO blood group on the diagnosis of von Willebrand disease.  Blood. 1987;  69 1691-1695
• 40 Nitu-Whalley I C, Lee C A, Griffioen A, Jenkins P V, Pasi K J. Type 1 von Willebrand disease-a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history.  Br J Haematol. 2000;  108 259-264
• 41 Bauduer F, Ducout L. Is the assessment of von Willebrand disease prevalence an achievable challenge? The example of the French Basque Country where blood group O and factor XI deficiency are highly prevalent.  J Thromb Haemost. 2004;  2 1724-1726
• 42 Sadler J E. Slippery criteria for von Willebrand disease type 1.  J Thromb Haemost. 2004;  2 1720-1723
• 43 Blombäck M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosing mild von Willebrand's disease.  Am J Hematol. 1992;  40 117-120
• 44 Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women.  N Engl J Med. 1980;  302 1093-1094
• 45 Miller C H, Dilley A B, Drews C, Richardson L, Evatt B. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle.  Thromb Haemost. 2002;  87 1082-1083
• 46 Onundarson P T. Treatment of menorrhagia in von Willebrand's disease.  Haemophilia. 1999;  5 76
• 47 Beller F K, Ebert C. Effects of oral contraceptives on blood coagulation. A review.  Obstet Gynecol Surv. 1985;  40 425-436
• 48 Prasad R N, Koh S C, Viegas O A, Ratnam S S. Effects on haemostasis after two year use of low dose combined oral contraceptive with gestodene or levonorgestrol.  Clin Appl Thromb Hemost. 1998;  5 60-70
• 49 Harris G M, Stendt C L, Vollenhoven B J, Gan T E, Tipping P G. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.  Am J Hematol. 1999;  60 175-180
• 50 Royal College of Obstetricians and Gynaecologists .The Initial Management of Menorrhagia-National Evidence-Based Clinical Guidelines. London; RCOG Press 1998
• 51 Royal College of Obstetricians and Gynaecologists .The Management of Menorrhagia in Secondary Care-National Evidence-Based Clinical Guidelines. London; RCOG Press 1999
• 52 Kadir R A, Lukes A S, Kouides P A, Fernandez H, Goudemand J. Management of excessive menstrual bleeding in women with hemostatic disorders.  Fertil Steril. 2005;  84 1352-1359
• 53 Wellington K, Wagstaff A J. Tranexamic acid: a review of its use in the management of menorrhagia.  Drugs. 2003;  63 1417-1433
• 54 Bonnar J, Sheppard B L. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid.  BMJ. 1996;  313 579-582
• 55 Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia.  Am J Obstet Gynecol. 1991;  164 879-883
• 56 British Medical Association and the Royal Pharmaceutical Society of Great Britain .British National Formulary. London; British Medical Association and the Royal Pharmaceutical Society of Great Britain 2004
• 57 Ong Y L, Hull D R, Mayne E E. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.  Haemophilia. 1998;  4 63-65
• 58 Rybo G. Tranexamic acid therapy: effective treatment in heavy menstrual bleeding: clinical update on safety.  Therapeutic Advances. 1991;  4 1-8
• 59 Callard G V, Litofsky F S, DeMerre L J. Menstruation in women with normal or artificially controlled cycles.  Fertil Steril. 1966;  17 684-688
• 60 Ramcharan S, Pellegrin F A, Ray R M, Hsu J P. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Volume III, an interim report: a comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives.  J Reprod Med. 1980;  25 345-372
• 61 Nilsson L, Rybo G. Treatment of menorrhagia.  Am J Obstet Gynecol. 1971;  110 713-720
• 62 Fraser I S, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.  Aust N Z J Obstet Gynaecol. 1991;  31 66-70
• 63 Foster P A. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost. 1995;  74 784-790
• 64 Sulak P J, Cressman B E, Waldrop E, Holleman S, Kuehl T J. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms.  Obstet Gynecol. 1997;  89 179-183
• 65 Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani P G. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis.  Fertil Steril. 2002;  77 52-61
• 66 Miller L, Notter K M. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial.  Obstet Gynecol. 2001;  98 771-778
• 67 Edelman A B, Gallo M F, Jensen J T, Nichols M D, Schulz K F, Grimes D A. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception.  Cochrane Database Syst Rev. 2005;  CD004695
• 68 Lethagen S, Harris A S, Sjorin E, Nilsson I M. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.  Thromb Haemost. 1987;  58 1033-1036
• 69 Mannucci P M, Aberg M, Nilsson I M, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.  Br J Haematol. 1975;  30 81-93
• 70 Edlund M, Blombäck M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin.  Blood Coagul Fibrinolysis. 2003;  14 593-598
• 71 Rodeghiero F, Castaman G, Mannucci P M. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.  Thromb Haemost. 1996;  76 692-696
• 72 Leissinger C, Becton D, Cornell Jr C, Cox G J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.  Haemophilia. 2001;  7 258-266
• 73 Kadir R A, Lee C A, Sabin C A, Pollard D, Economides D L. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study.  Haemophilia. 2002;  8 787-793
• 74 Edlund M, Blombäck M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time.  Blood Coagul Fibrinolysis. 2002;  13 225-231
• 75 Haynes P J, Hodgson H, Anderson A B, Turnbull A C. Measurement of menstrual blood loss in patients complaining of menorrhagia.  Br J Obstet Gynaecol. 1977;  84 763-768
• 76 Coulter A, Kelland J, Peto V, Rees M C. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice.  Int J Technol Assess Health Care. 1995;  11 456-471
• 77 Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding.  Cochrane Database Syst Rev. 2000;  CD001016
• 78 Irvine G A, Campbell-Brown M B, Lumsden M A, Heikkila A, Walker J J, Cameron I T. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.  Br J Obstet Gynaecol. 1998;  105 592-598
• 79 Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.  Cochrane Database Syst Rev. 2000;  CD000400
• 80 Silverberg S G, Haukkamaa M, Arko H, Nilsson C G, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices.  Int J Gynecol Pathol. 1986;  5 235-241
• 81 Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review.  BJOG. 2001;  108 74-86
• 82 Lahteenmaki P, Haukkamaa M, Puolakka J et al.. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy.  BMJ. 1998;  316 1122-1126
• 83 Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years.  Contraception. 2002;  65 129-132
• 84 Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial.  Contraception. 1994;  49 56-72
• 85 Sivin I, el Mahgoub S, McCarthy T et al.. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.  Contraception. 1990;  42 361-378
• 86 Xiao B, Wu S C, Chong J, Zeng T, Han L H, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia.  Fertil Steril. 2003;  79 963-969
• 87 Kingman C E, Kadir R A, Lee C A, Economides D L. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders.  BJOG. 2004;  111 1425-1428
• 88 Schaedel Z E, Dolan G, Powell M. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders.  Am J Obstet Gynecol. 2005;  193 1361-1363
• 89 Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding.  Cochrane Database Syst Rev. 2000;  CD000329
• 90 Lethaby A, Hickey M. Endometrial destruction techniques for heavy menstrual bleeding: a Cochrane review.  Hum Reprod. 2002;  17 2795-2806
• 91 Maresh M J, Metcalfe M A, McPherson K et al.. The VALUE national hysterectomy study: description of the patients and their surgery.  BJOG. 2002;  109 302-312
• 92 McPherson K, Metcalfe M A, Herbert A et al.. Severe complications of hysterectomy: the VALUE study.  BJOG. 2004;  111 688-694